ARS Pharmaceuticals (SPRY) Director Phillip Schneider Receives Award

What Happened
Phillip M. Schneider, a director of ARS Pharmaceuticals, was granted a derivative award covering 30,000 shares on June 24, 2026. The Form 4 reports the acquisition as an award/grant (code A) with a reported price of $0.00 and aggregate value $0. The filing indicates these are derivative securities (e.g., options or similar) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-26 (appears timely).
• Transaction type/code: Grant/Award (A) of derivative securities.
• Quantity: 30,000 shares; reported price: $0.00; reported total value: $0.
• Shares owned after transaction: Not disclosed in the provided excerpt.
• Footnote: The award vests in full on the earlier of June 24, 2027 or the date of the issuer’s 2027 annual meeting of stockholders.
• No indication in this filing that the award was part of a 10b5-1 plan, tax withholding, or a cashless sale.

Context
This was an award of derivative securities to a director—not an outright purchase or sale of common stock. Derivative grants typically have vesting and exercise terms that determine eventual value; the Form 4 here shows the vesting timing but does not specify exercise price or precise instrument type. Awards are compensation-related and don’t by themselves indicate immediate buying or selling intent. Retail investors who want valuation details should check ARS’s proxy statements or press releases for the award’s full terms.